ALK-Abelló A/S
ALK-B
Clasificación en acciones
#2416
ALK-Abelló A/S is a global leader in allergy solutions, with operations... ALK-Abelló A/S is a global leader in allergy solutions, with operations spanning Europe, North America, and other international regions. The company offers a comprehensive portfolio of treatments for allergic rhinitis and allergic asthma, featuring key products such as GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX. ALK-Abelló specializes in allergy immunotherapy, providing options like injections, sublingual drops, and tablets to address a wide range of sensitivities, including those to grass, ragweed, house dust mites, Japanese cedar, various tree pollens, and certain foods. Furthermore, the company engages with consumers through a digital healthcare ecosystem, a platform designed to connect with allergy sufferers early in their journey, offering tools, e-commerce solutions, and guidance to support and streamline access to immunotherapy. ALK-Abelló also provides essential diagnostic allergy services, including skin prick and blood tests, alongside emergency treatments such as intramuscular adrenaline injections for severe, life-threatening allergic reactions like anaphylaxis. The company was established in 1923 and is based in Hørsholm, Denmark.
Precio por acción
$36.42
Capitalización bursátil
$8.08B
Cambio (1 día)
-3.54%
Cambio (1 año)
10.29%
País
DK
Comercio ALK-Abelló A/S (ALK-B)
Categoría
Healthcare
Ingresos de ALK-Abelló A/S (ALK-B)
Ingresos en Jun 2026 TTM: $1.08B
Según los últimos informes financieros de ALK-Abelló A/S, los ingresos actuales de la empresa (TTM) son $1.08B. En 2023, la empresa obtuvo unos ingresos de $714.26M un aumento con respecto a los ingresos del año 2022, que fueron de $649.28M. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de ALK-Abelló A/S desde 2004 hasta 2026
Ingresos al final de cada año
| Año | Ingresos | Cambiar |
|---|---|---|
| 2026 (TTM) | $1.08B | 40.35% |
| 2024 | $772.54M | 8.16% |
| 2023 | $714.26M | 10.01% |
| 2022 | $649.28M | 8.42% |
| 2021 | $598.86M | 4.50% |
| 2020 | $573.06M | 16.63% |
| 2019 | $491.36M | 9.76% |
| 2018 | $447.68M | -4.54% |
| 2017 | $468.95M | 9.96% |
| 2016 | $426.48M | 13.93% |
| 2015 | $374.34M | -5.40% |
| 2014 | $395.69M | -4.38% |
| 2013 | $413.80M | -0.22% |
| 2012 | $414.70M | 1.41% |
| 2011 | $408.93M | 5.61% |
| 2010 | $387.20M | 3.63% |
| 2009 | $373.63M | 12.03% |
| 2008 | $333.50M | 2.67% |
| 2007 | $324.83M | 23.62% |
| 2006 | $262.76M | 36.41% |
| 2005 | $192.63M | -76.45% |
| 2004 | $817.87M | 0.00% |
Ingresos de empresas similares o competidoras
| Empresa | Ingresos | Diferencia de ingresos | País |
|---|---|---|---|
| $12.62B | 1,064.32% |
US
|
|
| $2.23B | 105.49% |
US
|
|
| $15.74B | 1,352.08% |
AU
|
|
| $6.02B | 455.34% |
NL
|
|
| - | - |
CH
|
